Korea Focuses on Phase-1 Bio Sales While China Advances to Phase-3 Trials

The article compares biotech development stages in Korea and China. Korean companies are concentrating on sales at Phase 1 of trials. In contrast, Chinese firms are moving projects through to Phase 3. The piece highlights differing strategic approaches in each market. It was published by 아시아경제 (Asian Economic). No specific companies or products are named in the summary. The contrast reflects varied regulatory and commercial environments. Analysts may watch how these strategies affect future market positions.